Buprenorphine
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1981
- First approval year
- 1981
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Buprenorphine
- Molecular weight
- 467.65
- Structure (SMILES)
- CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5
- brixadi
- Brixadi
- bupeaze
- Bupeaze
- buplast
- Buplast
- butec
- Butec
- butrans
- Butrans
- buvidal
- Buvidal
- hapoctasin
- Hapoctasin
- panitaz
- Panitaz
- prenotrix
- Prenotrix
- reletrans
- Reletrans
- sevodyne
- Sevodyne
- sublocade
- Sublocade
- temgesic
And 5 more, listed on the interactive page.
- (αS,5α,7α)-17-(Cyclopropylmethyl)-α-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-α-methyl-6,14-ethenomorphinan-7-methanol
- 6 14 ethenomorphinan 7 methanol 17 cyclopropylmethyl α 1 1 dimethylethyl 4 5 epoxy 18 19 dihydro 3 hydroxy 6 methoxy α methyl 5α 7α s
- 6 14 ethenomorphinan 7 methanol 17 cyclopropylmethyl α 1 1 dimethylethyl 4 5 epoxy 18 19 dihydro 3 hydroxy 6 methoxy α methyl αs 5α 7α
- 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-α-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-α-methyl-, (αS,5α,7α)-
- 6,14-Ethenomorphinan-7-methanol, 17-(cyclopropylmethyl)-α-(1,1-dimethylethyl)-4,5-epoxy-18,19-dihydro-3-hydroxy-6-methoxy-α-methyl-, [5α,7α(S)]-
- alks 5461 component buprenorphine
- ALKS-5461 COMPONENT BUPRENORPHINE
- brixadi
- Brixadi
- Brixadi (Injectable Buprenorphine)
- buprenorfina
- Buprenorfina
- buprenorphin
- Buprenorphin
- buprenorphine
- Buprenorphine
- BUPRENORPHINE [EMA EPAR]
- BUPRENORPHINE [EP IMPURITY]
- BUPRENORPHINE [EP MONOGRAPH]
- buprenorphine [INN]
- BUPRENORPHINE [JAN]
- BUPRENORPHINE [MART.]
- BUPRENORPHINE [MI]
- BUPRENORPHINE [ORANGE BOOK]
- BUPRENORPHINE [VANDF]
And 24 more, listed on the interactive page.
- CAS registry numbers
- 52485-79-7
- ChEMBL ID
- CHEMBL511142
- InChIKey
- RMRJXGBAOAMLHD-CTAPUXPBSA-N
- RxNorm IDs (RxCUI)
- 1819
- FDA ingredient codes (UNII)
- 40D3SCR4GZ
- N02AE01
- N07BC01
- N07BC51
Sources for recorded values
- 644073
- 9848990
- Applicant
- KNOA PHARMA
- Approval date
- 30 Jun 2010
- Application number
- NDA021306
- Status
- Authorised
- Status date
- 20 Nov 2018
- Authorisation date
- 20 Nov 2018
- Approved indications
- Treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over.
- Product number
- EMEA/H/C/004651
- Authorisation holder
- Camurus AB
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 0
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- No
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- Opioid-Related Disorders
European medicines record
- Patents
- 20
- Designations
- 1
- Earliest recorded loss of exclusivity
- 22 Jun 2038
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Boxed warning
- Yes
- Pharmacology name
- buprenorphine
- Type
- Synthetic organic
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Parenteral
- topical
- Mechanism
- Kappa opioid receptor agonist
- Action type
- Agonist
- Target
- Kappa-type opioid receptor
- Protein identifier
- P41145
- Mechanism
- Mu opioid receptor agonist
- Action type
- Agonist
- Target
- Mu-type opioid receptor
- Protein identifier
- P35372
- Action
- Antagonist
- Action type
- Antagonist
- Target
- κ receptor
- Gene symbol
- OPRK1
- Protein identifier
- P41145
- Affinity units
- pKi
- Primary target
- Yes
- Action
- Partial agonist
- Action type
- PARTIAL_AGONIST
- Target
- μ receptor
- Gene symbol
- OPRM1
- Protein identifier
- P35372
- Median affinity
- 8.8
- Affinity units
- pKi
- Primary target
- Yes
- Mechanism
- Kappa opioid receptor agonist
- Action type
- Agonist
- Target
- Kappa-type opioid receptor
- Mechanism
- Mu opioid receptor agonist
- Action type
- Agonist
- Target
- Mu-type opioid receptor
- Action type
- Antagonist
- Gene symbol
- OPRD1
- Protein identifier
- P41143
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- Antagonist
- Gene symbol
- OPRK1
- Protein identifier
- P41145
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- PARTIAL AGONIST
- Gene symbol
- OPRM1
- Protein identifier
- P35372
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000181
- Subject identifier
- D002294
- Condition
- HIV Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000764
- Subject identifier
- D015658
- Condition
- Stress Disorders, Post-Traumatic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001358
- Subject identifier
- D013313
- Condition
- Cocaine-Related Disorders
- Highest recorded phase
- 3
- Condition identifier
- EFO:0002610
- Subject identifier
- D019970
- Condition
- Hepatitis C
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003047
- Subject identifier
- D006526
- Condition
- Pain
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003843
- Subject identifier
- D010146
- Condition
- Acute Pain
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003843
- Subject identifier
- D059787
- Condition
- Substance-Related Disorders
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003890
- Subject identifier
- D019966
- Condition
- Heroin Dependence
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004240
- Subject identifier
- D006556
- Condition
- Amphetamine-Related Disorders
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004701
- Subject identifier
- D019969
- Condition
- Opioid-Related Disorders
- Highest recorded phase
- 4
- Condition identifier
- EFO:0005611
- Subject identifier
- D009293
- Condition
- Morphine Dependence
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005612
- Subject identifier
- D009021
- Condition
- Neuralgia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005762
- Subject identifier
- D009437
- Condition
- Neonatal Abstinence Syndrome
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005799
- Subject identifier
- D009357
- Condition
- Substance Withdrawal Syndrome
- Highest recorded phase
- 3
- Condition identifier
- EFO:0005800
- Subject identifier
- D013375
- Condition
- Toothache
- Highest recorded phase
- 2
- Condition identifier
- EFO:0010072
- Subject identifier
- D014098
- Condition
- Opioid-Related Disorders
- Highest recorded phase
- 4
- Condition identifier
- EFO:0010702
- Subject identifier
- D009293
- Condition
- Drug Overdose
- Highest recorded phase
- 4
- Condition identifier
- EFO:0020911
- Subject identifier
- D062787
- Condition
- Rotator Cuff Injuries
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001250
- Subject identifier
- D000070636
- Condition
- Back Pain
- Highest recorded phase
- 3
- Condition identifier
- HP:0003418
- Subject identifier
- D001416
- Condition
- Low Back Pain
- Highest recorded phase
- 3
- Condition identifier
- HP:0003419
- Subject identifier
- D017116
- Condition
- Intervertebral Disc Degeneration
- Highest recorded phase
- 3
- Condition identifier
- HP:0008419
- Subject identifier
- D055959
- Condition
- Chronic Pain
- Highest recorded phase
- 4
- Condition identifier
- HP:0012532
- Subject identifier
- D059350
- Condition
- Depressive Disorder, Major
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0002009
- Subject identifier
- D003865
- Condition
- Depressive Disorder
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0002050
- Subject identifier
- D003866
And 4 more, listed on the interactive page.
- Condition identifier
- EFO_0000181
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000342
- Condition identifier
- EFO_0000764
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001074
- Condition identifier
- EFO_0001358
- Highest recorded phase
- 2
- Condition identifier
- EFO_0002610
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003890
- Condition identifier
- EFO_0004240
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004320
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004616
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004701
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004888
- Condition identifier
- EFO_0005611
- Condition identifier
- EFO_0005799
- Highest recorded phase
- 3
- Condition identifier
- EFO_0005800
- Condition identifier
- EFO_0007624
- Highest recorded phase
- 3
- Condition identifier
- EFO_0009842
- Highest recorded phase
- 1
- Condition identifier
- EFO_0010445
- Highest recorded phase
- 2
- Condition identifier
- EFO_0010702
- Highest recorded phase
- 3
- Condition identifier
- EFO_0020911
- Condition identifier
- EFO_0020911
- Highest recorded phase
- 4
- Condition identifier
- EFO_0022195
- Highest recorded phase
- 1
- Condition identifier
- EFO_0022861
- Highest recorded phase
- 3
- Condition identifier
- EFO_0801084
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001250
And 35 more, listed on the interactive page.
- Warning
- Black Box Warning
- Effect
- misuse
- Warning
- Black Box Warning
- Effect
- respiratory toxicity
- Warning
- Black Box Warning
- Country
- United States
- Warning
- Black Box Warning
- Effect
- misuse
- Country
- United States
- Warning
- Black Box Warning
- Effect
- respiratory toxicity
- Country
- United States
- Event
- alcohol abuse
- Reports
- 81
- Reporting signal score
- 190.505
- Event
- application site burn
- Reports
- 157
- Reporting signal score
- 523.025
- Event
- application site erythema
- Reports
- 369
- Reporting signal score
- 1,001.81
- Event
- application site irritation
- Reports
- 118
- Reporting signal score
- 290.019
- Event
- application site pain
- Reports
- 217
- Reporting signal score
- 447.647
- Event
- application site pruritus
- Reports
- 500
- Reporting signal score
- 1,674.25
- Event
- application site rash
- Reports
- 281
- Reporting signal score
- 856.629
- Event
- application site vesicles
- Reports
- 198
- Reporting signal score
- 647.215
- Event
- drug abuse
- Reports
- 797
- Reporting signal score
- 1,320.97
- Event
- drug delivery system removal
- Reports
- 42
- Reporting signal score
- 196.876
- Event
- drug dependence
- Reports
- 694
- Reporting signal score
- 1,563.1
- Event
- drug detoxification
- Reports
- 68
- Reporting signal score
- 251.605
- Event
- drug screen negative
- Reports
- 135
- Reporting signal score
- 529.095
- Event
- drug screen positive
- Reports
- 124
- Reporting signal score
- 254.724
- Event
- drug withdrawal syndrome
- Reports
- 1,368
- Reporting signal score
- 3,448.03
- Event
- drug withdrawal syndrome neonatal
- Reports
- 333
- Reporting signal score
- 875.297
- Event
- euphoric mood
- Reports
- 137
- Reporting signal score
- 279.178
- Event
- hyperhidrosis
- Reports
- 369
- Reporting signal score
- 207.744
- Event
- inadequate analgesia
- Reports
- 277
- Reporting signal score
- 850.497
- Event
- injection site extravasation
- Reports
- 129
- Reporting signal score
- 187.137
- Event
- injection site infection
- Reports
- 89
- Reporting signal score
- 218.046
- Event
- injection site pain
- Reports
- 518
- Reporting signal score
- 180.248
- Event
- miosis
- Reports
- 168
- Reporting signal score
- 293.724
- Event
- oral administration complication
- Reports
- 52
- Reporting signal score
- 184.814
- Event
- respiratory depression
- Reports
- 142
- Reporting signal score
- 211.037
And 3 more, listed on the interactive page.
- NCT00000202
- NCT00000203
- NCT00000204
- NCT00000205
- NCT00000206
- NCT00000207
- NCT00000208
- NCT00000209
- NCT00000216
- NCT00000219
- NCT00000220
- NCT00000221
- NCT00000222
- NCT00000223
- NCT00000224
- NCT00000225
- NCT00000226
- NCT00000227
- NCT00000228
- NCT00000229
- NCT00000230
- NCT00000231
- NCT00000232
- NCT00000233
- NCT00000234
And 214 more, listed on the interactive page.
- Dose
- Up to 8 mg/2 mg on Day 1; up to 16 mg/4 mg on Day 2; generally 4 mg/1 mg to 24 mg/6 mg per day for maintenance
- Route
- Sublingual or buccal
- How often
- Once daily
- Do not cut, chew, or swallow
- Take whole
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 2
- Polar surface area
- 62.16
- Calculated partition coefficient (ALogP)
- 4.41
- Calculated partition coefficient (XLogP)
- 5
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 4
- Heavy atoms
- 34
- Molecular formula
- C29H41NO4
- Monoisotopic mass
- 467.30355879
- Natural product
- Yes
- 0093-3239
- 0093-3656
- 0093-3657
- 0093-3658
- 0093-3659
- 3215-1521
- 3215-1522
- 3215-1523
- 3215-1524
- 3215-1525
- 42858-353
- 42858-493
- 42858-586
- 42858-750
- 42858-839
- 47781-406
- 47781-407
- 47781-408
- 47781-419
- 50742-372
- 50742-373
- 50742-374
- 50742-375
- 50742-376
- 58284-208
And 22 more, listed on the interactive page.
- Recorded assays
- 3
- Active assays
- 3
- Confirmatory
- Other
- Analgesics, Opioid
- Narcotic Antagonists
- Narcotics
Distribution coefficient (LogD)
- Median
- 3.585
- Mean
- 3.15
- Minimum
- 0.45
- Maximum
- 4.98
- Unit
- unitless
- Assays
- 4
- Standard deviation
- 1.93696
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- LogD
Cardiac potassium channel inhibition
- Median
- 7,764.53
- Mean
- 7,764.53
- Minimum
- 7,585.78
- Maximum
- 7,943.28
- Unit
- nM
- Assays
- 2
- Standard deviation
- 252.791
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- IC50
Related records
Trials (402)
- 4-drug Nerve Block Versus Plain Local Anesthetic for Knee and Hip Arthroplasty Analgesia in Veterans
- A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence
- A Bundled Intervention to End Opioid Overdoses
- A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use
- A Double-Blind Study of Buprenorphine Treatment of Acute Suicidality
- A Pragmatic Randomized Control Trial Comparing Models of Care in the Management of Prescription Opioid Misuse
- A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED)
- A Randomized Acceptability and Safety Study of the Transfer From Subutex to Suboxone in Opioid- Dependent Subjects (Study P04843)(COMPLETED)
- A Single-Dose Study of an Investigational Capsule Formulation of 2 mg/0.5 mg Buprenorphine/Naloxone
- A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction
- A Stepwise Strategy Utilizing Buprenorphine and Methadone
- A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine Responders
- A Study Comparing Norspan Patch and Oral Tramadol
- A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder
- A Study of Adult Outpatients With Opioid Dependence Transitioned From a Daily SL Buprenorphine to Probuphine® Subdermal Implants
- A Study of Brenipatide in Participants With Opioid Use Disorder
- A Study of the Abuse Liability Potential of ALKS 5461 in Healthy, Non-Dependent, Recreational Opioid Users
- A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/Naloxone
- A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Opioid Use Disorder
- A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder
Approved for (4)
- Drug dependence
- Opiate dependence
- Opioid abuse
- Substance abuse
In development for (21)
- Cocaine dependence Phase 3
- Depressive disorder Phase 3
- Head and neck squamous cell carcinoma Phase 2
- Hepatitis C virus infection Phase 1
- Heroin dependence Phase 3
- HIV infectious disease Phase 3
- Intervertebral disk degenerative disorder Phase 3
- Major depressive disorder Phase 3
- Methamphetamine dependence Phase 2
- Migraine disorder Phase 2
- Morphine dependence Phase 3
- Neonatal abstinence syndrome Phase 3
- Neuralgia Phase 3
- Osteoarthritis Phase 3
- Osteoarthritis, knee Phase 3
- Post-traumatic stress disorder Phase 2
- Psychiatric disorder Phase 3
- Rotator cuff syndrome Phase 2
- Schizophrenia Phase 2
- Sickle cell disease Phase 2
Other linked conditions (4)
- Cancer
- Chronic pancreatitis
- Complex regional pain syndrome
- Morbid obesity